bicalutamid-teva 50 mg
teva pharmaceuticals slovakia s.r.o., slovensko - bikalutamid - 44 - cytostatica
bicalutamid-teva 150 mg
teva pharmaceuticals slovakia s.r.o., slovensko - bikalutamid - 44 - cytostatica
bicusan 150 mg
actavis group ptc ehf., island - bikalutamid - 44 - cytostatica
binabic 50 mg
vipharm s.a., poľsko - bikalutamid - 44 - cytostatica
bicacel 150 mg
glenmark pharmaceuticals s.r.o., Česká republika - bikalutamid - 44 - cytostatica
bicalutamide pharmevid 150 mg
pharmevid s.r.o., slovensko - bikalutamid - 44 - cytostatica
bicagelan 150 mg filmom obalené tablety
g.l. pharma gmbh, rakúsko - bikalutamid - 44 - cytostatica
caprodez
ardez pharma, spol. s r.o., Česká republika - bikalutamid - 44 - cytostatica
xtandi
astellas pharma europe b.v. - enzalutamide - prostatické nádory - endokrinná terapia - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
flutasin 250 mg
actavis group ptc ehf. - flutamid - 44 - cytostatica